Approach and management to patients with neurological disorders reporting sexual dysfunction
- PMID: 35405093
- DOI: 10.1016/S1474-4422(22)00036-9
Approach and management to patients with neurological disorders reporting sexual dysfunction
Abstract
Sexual difficulties are common in patients with neurological disorders, and different domains of sexual function-desire, arousal, orgasm, and ejaculation-can be affected. Advances in the past 7 years in structural and functional neuroimaging have contributed to a greater understanding of the neural pathways involved in the regulation of sexual functions in health and disease, and this increased knowledge might help with development of future therapeutic strategies. A comprehensive assessment of patients includes history taking-covering the different domains of dysfunction, and primary, secondary, and tertiary contributory factors-as well as clinical examination in select patients (ie, patients for whom an associated non-neurological cause for sexual dysfunction is suspected). Investigations, such as assessment of associated cardiovascular risk factors, might also be indicated in specific situations. PDE5A inhibitors and intracavernosal injections of the prostaglandin alprostadil are effective for treating erectile dysfunction; however, options for managing other domains of sexual dysfunction in men and women remain poor. Research into different domains of sexual dysfunction is likely to lead to additional therapeutic strategies in the future.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests CH is supported in part by scholar grants from the Société Interdisciplinaire Francophone d'UroDynamique et de Pelvi Périnéologie (the French-speaking society of urodynamics), Lilial and the Groupe de Recherche Clinique en Neuro-Urologie (GRC-01) at Université Pierre-et-Marie-Curie, the French Society of Physical and Rehabilitation Medicine, and from the endowment fund Renaître. SM reports personal fees from Helaglobe, Medtronic, Wellspect, Coloplast, Bard, and Edi Ermes; non-financial support from Hollister; and is an executive board member of the Italian Urodynamic Society and member of the associate panel for Neuro-Urology Guidelines of the European Association of Urology. GA reports personal fees from Coloplast and Hollister, non-financial support from AbbVie, and is board member of the French Urodynamic Society. JNP is supported in part by funding from the UK Department of Health National Institute for Health Research Biomedical Research Centres funding scheme, and reports royalties from Cambridge University Press and honoraria from Allergan, Coloplast, Novartis, and Wellspect. GDP declares no competing interests.
Comment in
-
Considering the neurological health needs of LGBTQIA people.Lancet Neurol. 2022 Nov;21(11):960. doi: 10.1016/S1474-4422(22)00346-5. Lancet Neurol. 2022. PMID: 36270303 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous